This is interesting, as treatment with monoclonal antibodies against TNFα in MS has shown increased disease activity,57, 58 and treatment with neutralizing antibodies toward IL‐12/IL‐23p40 can be used to treat several autoimmune diseases,59 but no effect was seen in MS.60 The gene discussed is TNF; the disease is myeloid sarcoma.